| Jul 24 |
Verastem Oncology slumps 26%, prices $55M offering
|
| Jul 24 |
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
|
| Jul 23 |
Verastem Oncology announces proposed offering of common stock, warrants and pre-funded warrants
|
| Jul 23 |
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
|
| Jul 15 |
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
|
| Jul 15 |
Verastem announces dosing of first patient in trial of KRAS G12D inhibitor
|
| Jul 12 |
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
|
| Jul 12 |
Verastem spikes as dosing for lead program starts in China
|
| Jul 12 |
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
|
| Jul 1 |
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
|
